Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model-Reference-Cited by-同舟云学术

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model

Published:2021-01 Issue: Volume:534 Page:1-7
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Kobayashi Keigo,Terai Hideki^ORCID,Yasuda Hiroyuki,Hamamoto Junko^ORCID,Hayashi Yuichiro,Takeuchi Osamu,Mitsuishi Yoichiro,Masuzawa Keita,Manabe Tadashi,Ikemura Shinnosuke,Kawada Ichiro^ORCID,Suzuki Yukio,Soejima Kenzo,Fukunaga Koichi

Funder

Japan Society for the Promotion of Science

Takeda Science Foundation

Ichiro Kanehara Foundation

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference32 articles.

1. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008

2. New driver mutations in non-small-cell lung cancer;Pao;Lancet Oncol.,2011

3. Lung cancer;Herbst;N. Engl. J. Med.,2008

4. Targeted therapy in non-small-cell lung cancer--is it becoming a reality?, Nature reviews;Janku;Clin. Oncol.,2010

5. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time;Gerber;Canc. Cell,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies;Frontiers in Oncology;2022-02-16

2. Sotorasib. GTPase KRAS (G12C mutant) inhibitor, Treatment of non-small cell lung cancer, Treatment of colorectal cancer, Treatment of solid tumors;Drugs of the Future;2021